When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–
15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have …

Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal
tract. Surgery is the standard treatment for localised disease, but the risk of relapse and …

Opinion statement Gastrointestinal stromal tumor (GIST), though rare, is the most common
mesenchymal tumors of the gastrointestinal tract. KIT or PDGFRα mutation plays as an …

Gastrointestinal stromal tumor (GIST) is the most common sarcoma located in
gastrointestinal tract and derived from the interstitial cell of Cajal (ICC) lineage. Both ICC …

Prior to the early 2000s, patients with advanced gastrointestinal stromal tumors (GIST) had
very poor prognoses owing to a lack of effective therapies. The development of tyrosine …

Most gastrointestinal stromal tumors (GIST) are driven by activating mutations in Proto-
oncogene c-KIT (KIT) or PDGFRA receptor tyrosine kinases (RTK). The emergence of …

Purpose: The efficacy of the selective KIT/PDGFRA inhibitor avapritinib (300 mg once daily)
was explored in patients with non–PDGFRA-mutant gastrointestinal stromal tumors (GISTs) …

Pimitespib (TAS-116) is the first heat shock protein 90 (HSP90) inhibitor approved in Japan,
and it is indicated for the treatment of gastrointestinal stromal tumors (GIST) that have …

Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal
neoplasms of the gastrointestinal tract. The gold standard for the diagnosis of GISTs is …